{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:34:05Z","timestamp":1793039645473,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005972","name":"German Cancer Aid","doi-asserted-by":"publisher","award":["70114388"],"award-info":[{"award-number":["70114388"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.radonc.2025.110907","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T11:14:11Z","timestamp":1745579651000},"page":"110907","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Impact of estimated dose of radiation to immune cells (EDRIC) in locally advanced Non-Small-Cell lung Cancer: A secondary analysis of the multicenter randomized PET-Plan trial"],"prefix":"10.1016","volume":"208","author":[{"given":"Cas Stefaan","family":"Dejonckheere","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youn\u00e8ss","family":"Nour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Sahlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Tobias","family":"Engelhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelkhalek","family":"Hammi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simeon Ari","family":"Barth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Schimek-Jasch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Adebahr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Hecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelius","family":"Waller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Severin","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Miederer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Brose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Binder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochem","family":"K\u00f6nig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Rimner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca-Ligia","family":"Grosu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Nestle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Gkika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2025.110907_b0005","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.radonc.2025.110907_b0010","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.radonc.2025.110907_b0015","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1097\/JTO.0b013e3182429682","article-title":"Defining local-regional control and its importance in locally advanced non-small cell lung carcinoma","volume":"7","author":"Machtay","year":"2012","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.radonc.2025.110907_b0020","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1200\/JCO.2015.62.6812","article-title":"Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE)","volume":"33","author":"Eberhardt","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.radonc.2025.110907_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109492","article-title":"(18)F-FDG-PET guided vs whole tumour radiotherapy dose escalation in patients with locally advanced non-small cell lung cancer (PET-Boost): Results from a randomised clinical trial","volume":"181","author":"Cooke","year":"2023","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.radonc.2025.110907_b0030","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S1470-2045(14)71207-0","article-title":"Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial p","volume":"16","author":"Bradley","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.radonc.2025.110907_b0035","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1200\/JCO.19.01162","article-title":"Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non\u2013Small-Cell Lung Cancer","volume":"38","author":"Bradley","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.radonc.2025.110907_b0040","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13246193","article-title":"Higher Radiation Dose to the Immune Cells Correlates with Worse Tumor Control and Overall Survival in Patients with Stage III NSCLC: A Secondary Analysis of RTOG0617","volume":"13","author":"Jin","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.radonc.2025.110907_b0045","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3109\/07357907.2012.762780","article-title":"The etiology of treatment-related lymphopenia in patients with malignant gliomas: modeling radiation dose to circulating lymphocytes explains clinical observations and suggests methods of modifying the impact of radiation on immune cells","volume":"31","author":"Yovino","year":"2013","journal-title":"Cancer Invest."},{"key":"10.1016\/j.radonc.2025.110907_b0050","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3109\/07357907.2013.767342","article-title":"Treatment-related lymphopenia in patients with stage III non-small-cell lung cancer","volume":"31","author":"Campian","year":"2013","journal-title":"Cancer Invest."},{"key":"10.1016\/j.radonc.2025.110907_b0055","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/j.jtho.2020.06.008","article-title":"Radiotherapy-Related Lymphopenia Affects Overall Survival in Patients With Lung Cancer","volume":"15","author":"Abravan","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.radonc.2025.110907_b0060","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.ijrobp.2021.07.1695","article-title":"The Influence of Severe Radiation-Induced Lymphopenia on Overall Survival in Solid Tumors: A Systematic Review and Meta-Analysis","volume":"111","author":"Damen","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.radonc.2025.110907_b0065","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1470-2045(20)30013-9","article-title":"Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial","volume":"21","author":"Nestle","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.radonc.2025.110907_b0070","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.radonc.2021.07.017","article-title":"Impact of radiotherapy protocol adherence in NSCLC patients treated with concurrent chemoradiation: RTQA results of the PET-Plan trial","volume":"163","author":"Gkika","year":"2021","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.radonc.2025.110907_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2025.02.041","article-title":"Impact of Different Mediastinal Staging Modalities on Target Volume Delineation in Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the Multicenter Randomized PET-Plan Trial","author":"Rimner","year":"2025","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.radonc.2025.110907_b0080","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s40644-023-00567-6","article-title":"PET\/CT reading for relapse in non-small cell lung cancer after chemoradiotherapy in the PET-Plan trial cohort","volume":"23","author":"Brose","year":"2023","journal-title":"Cancer Imaging"},{"key":"10.1016\/j.radonc.2025.110907_b0085","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.ijrobp.2019.05.064","article-title":"Impact of Radiation Dose to the Host Immune System on Tumor Control and Survival for Stage III Non-Small Cell Lung Cancer Treated with Definitive Radiation Therapy","volume":"105","author":"Ladbury","year":"2019","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.radonc.2025.110907_b0090","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.radonc.2021.03.026","article-title":"Is a higher estimated dose of radiation to immune cells predictive of survival in patients with locally advanced non-small cell lung cancer treated with thoracic radiotherapy?","volume":"159","author":"Yin","year":"2021","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.radonc.2025.110907_b0095","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.radonc.2021.06.020","article-title":"Impact of effective dose to immune cells (EDIC) on lymphocyte nadir and survival in limited-stage SCLC","volume":"162","author":"Yu","year":"2021","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.radonc.2025.110907_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.110030","article-title":"The effective radiation dose to immune cells predicts lymphopenia and inferior cancer control in locally advanced NSCLC","volume":"190","author":"Friedes","year":"2024","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.radonc.2025.110907_b0105","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1016\/j.ijrobp.2024.07.1831","article-title":"Impact of Radiation Dose to the Immune Cells on Lymphopenia for Stage IV Non-Small Cell Lung Cancer Receiving Immunotherapy and Radiotherapy","volume":"120","author":"He","year":"2024","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.radonc.2025.110907_b0110","doi-asserted-by":"crossref","first-page":"17","DOI":"10.14338\/IJPT-20-00086","article-title":"Radiation-Induced Lymphopenia Risks of Photon Versus Proton Therapy for Esophageal Cancer Patients","volume":"8","author":"Ebrahimi","year":"2021","journal-title":"Int J Part Ther"},{"key":"10.1016\/j.radonc.2025.110907_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.110019","article-title":"Proton and photon radiotherapy in stage III NSCLC: Effects on hematological toxicity and adjuvant immune therapy","volume":"190","author":"Cortiula","year":"2024","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.radonc.2025.110907_b0120","article-title":"Immune System Dose With Proton Versus Photon Radiotherapy for Treatment of Locally Advanced NSCLC","volume":"12","author":"Patel","year":"2024","journal-title":"Int J Part Ther"},{"key":"10.1016\/j.radonc.2025.110907_b0125","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/S1470-2045(24)00320-6","article-title":"Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [18F]FDG-PET tumour residual uptake at 42 Gy (RTEP7\u2013IFCT-1402): a multicentre, randomised, controll","volume":"25","author":"Vera","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.radonc.2025.110907_b0130","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.ijrobp.2024.03.030","article-title":"Efficacy and Toxicity of Moderately Hypofractionated Radiation Therapy with Helical TomoTherapy Versus Conventional Radiation Therapy in Patients with Unresectable Stage III Non-Small Cell Lung Cancer Receiving Concurrent Chemotherapy: A Multicenter, Rand","volume":"120","author":"Zhang","year":"2024","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.radonc.2025.110907_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109804","article-title":"Impact of radiation dose to the immune system on disease progression and survival for early-stage non-small cell lung cancer treated with stereotactic body radiation therapy","volume":"186","author":"Wang","year":"2023","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.radonc.2025.110907_b0140","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jtho.2022.09.004","article-title":"Cardiac Function Modifies the Impact of Heart Base Dose on Survival: A Voxel-Wise Analysis of Patients With Lung Cancer From the PET-Plan Trial","volume":"18","author":"Craddock","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.radonc.2025.110907_b0145","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.jtho.2023.01.085","article-title":"Demystifying the Results of RTOG 0617: Identification of Dose Sensitive Cardiac Subregions Associated With Overall Survival","volume":"18","author":"McWilliam","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.radonc.2025.110907_b0150","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1186479","article-title":"Impact of radiation on host immune system in patients treated with chemoradiotherapy and durvalumab consolidation for unresectable locally advanced non-small cell lung cancer","volume":"13","author":"Pasquier","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.radonc.2025.110907_b0155","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ijrobp.2016.10.046","article-title":"Does Unintentional Splenic Radiation Predict Outcomes After Pancreatic Cancer Radiation Therapy?","volume":"97","author":"Chadha","year":"2017","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"2","key":"10.1016\/j.radonc.2025.110907_b0160","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ijrobp.2024.08.035","article-title":"Dose-Response Relationships Between Radiation Exposure, Bone Marrow Function as Measured by 18F-Fluorothymidine Positron Emission Tomography, and Lymphocyte Counts During Chemoradiation for Non-Small Cell Lung Cancer","volume":"121","author":"MacManus","year":"2025","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.radonc.2025.110907_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110521","article-title":"Impact of mediastinal tumor burden and lymphatic spread in locally advanced non-small-cell lung cancer: A secondary analysis of the multicenter randomized PET-Plan trial","volume":"200","author":"Gkika","year":"2024","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.radonc.2025.110907_b0170","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1186\/s12885-024-12699-4","article-title":"Higher immune cell radiation dose is correlated with poor tumor control and survival in patients with non-small cell lung cancer receiving postoperative radiotherapy","volume":"24","author":"Ma","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.radonc.2025.110907_b0175","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.radonc.2020.02.015","article-title":"The impact of the effective dose to immune cells on lymphopenia and survival of esophageal cancer after chemoradiotherapy","volume":"146","author":"Xu","year":"2020","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.radonc.2025.110907_b0180","first-page":"380","article-title":"Impact of Radiation Dose to Circulating Immune Cells on Tumor Control and Survival in Esophageal Cancer","volume":"38","author":"Cai","year":"2021","journal-title":"Cancer Biother. Radiopharm."},{"key":"10.1016\/j.radonc.2025.110907_b0185","doi-asserted-by":"crossref","DOI":"10.3791\/67243","article-title":"Clinical Factors Influencing the Radiation Dose of Circulating Immune Cells during Radiotherapy for Small Cell Lung Cancer","author":"Tang","year":"2024","journal-title":"JoVE e67243"},{"key":"10.1016\/j.radonc.2025.110907_b0190","doi-asserted-by":"crossref","first-page":"55008","DOI":"10.1088\/1361-6560\/ab6c41","article-title":"4D blood flow model for dose calculation to circulating blood and lymphocytes","volume":"65","author":"Hammi","year":"2020","journal-title":"Phys. Med. Biol."},{"key":"10.1016\/j.radonc.2025.110907_b0195","doi-asserted-by":"crossref","DOI":"10.1088\/1361-6560\/acdcdc","article-title":"4D dosimetric-blood flow model: impact of prolonged fraction delivery times of IMRT on the dose to the circulating lymphocytes","volume":"68","author":"Hammi","year":"2023","journal-title":"Phys. Med. Biol."}],"updated-by":[{"DOI":"10.1016\/j.radonc.2026.111382","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000}}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814025002026?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814025002026?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T01:57:33Z","timestamp":1769047053000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814025002026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":39,"alternative-id":["S0167814025002026"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2025.110907","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of estimated dose of radiation to immune cells (EDRIC) in locally advanced Non-Small-Cell lung Cancer: A secondary analysis of the multicenter randomized PET-Plan trial","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2025.110907","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"110907"}}